Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $6.81 and last traded at $6.87, with a volume of 73,003 shares trading hands. The stock had previously closed at $7.01.

Several equities analysts have recently issued reports on NEOS shares. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Wells Fargo & Co. reissued a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. Royal Bank Of Canada decreased their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $15.00 price target on shares of Neos Therapeutics in a report on Tuesday, July 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Neos Therapeutics has a consensus rating of “Buy” and an average target price of $21.75.

The company’s market capitalization is $112.17 million. The firm has a 50-day moving average price of $8.57 and a 200 day moving average price of $9.50.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities research analysts predict that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.

In related news, insider Juergen Martens acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was acquired at an average price of $9.90 per share, with a total value of $99,000.00. Following the purchase, the insider now directly owns 10,000 shares in the company, valued at $99,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP raised its stake in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.